These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 32329226)

  • 1. Complement Receptor Targeted Liposomes Encapsulating the Liver X Receptor Agonist GW3965 Accumulate in and Stabilize Atherosclerotic Plaques.
    Benne N; Martins Cardoso R; Boyle AL; Kros A; Jiskoot W; Kuiper J; Bouwstra J; Van Eck M; Slütter B
    Adv Healthc Mater; 2020 May; 9(10):e2000043. PubMed ID: 32329226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr
    Yu M; Amengual J; Menon A; Kamaly N; Zhou F; Xu X; Saw PE; Lee SJ; Si K; Ortega CA; Choi WI; Lee IH; Bdour Y; Shi J; Mahmoudi M; Jon S; Fisher EA; Farokhzad OC
    Adv Healthc Mater; 2017 Oct; 6(20):. PubMed ID: 28730752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis.
    Zhang XQ; Even-Or O; Xu X; van Rosmalen M; Lim L; Gadde S; Farokhzad OC; Fisher EA
    Adv Healthc Mater; 2015 Jan; 4(2):228-36. PubMed ID: 25156796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Foam Cell Targeted Liposomes Co-Encapsulating Superoxide Dismutase and Catalase to Attenuate Atherosclerosis by Inhibiting Oxidative Stress.
    Zhang S; Liu D; Zhang J; Liu S; Sun R; Huo R; Cui C
    Discov Med; 2024 Feb; 36(181):343-354. PubMed ID: 38409839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels.
    van der Hoorn J; Lindén D; Lindahl U; Bekkers M; Voskuilen M; Nilsson R; Oscarsson J; Lindstedt E; Princen H
    Br J Pharmacol; 2011 Apr; 162(7):1553-63. PubMed ID: 21175581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo.
    Naik SU; Wang X; Da Silva JS; Jaye M; Macphee CH; Reilly MP; Billheimer JT; Rothblat GH; Rader DJ
    Circulation; 2006 Jan; 113(1):90-7. PubMed ID: 16365197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipidomic analysis of human primary hepatocytes following LXR activation with GW3965 identifies AGXT2L1 as a main target associated to changes in phosphatidylethanolamine.
    Santinha D; Klopot A; Marques I; Ellis E; Jorns C; Johansson H; Melo T; Antonson P; Jakobsson T; Félix V; Gustafsson JÅ; Domingues MR; Mode A; Helguero LA
    J Steroid Biochem Mol Biol; 2020 Apr; 198():105558. PubMed ID: 31783151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chlamydia pneumoniae-induced foam cell formation requires MyD88-dependent and -independent signaling and is reciprocally modulated by liver X receptor activation.
    Chen S; Sorrentino R; Shimada K; Bulut Y; Doherty TM; Crother TR; Arditi M
    J Immunol; 2008 Nov; 181(10):7186-93. PubMed ID: 18981140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The secretome of liver X receptor agonist-treated early outgrowth cells decreases atherosclerosis in Ldlr-/- mice.
    Rasheed A; Shawky SA; Tsai R; Jung RG; Simard T; Saikali MF; Hibbert B; Rayner KJ; Cummins CL
    Stem Cells Transl Med; 2021 Mar; 10(3):479-491. PubMed ID: 33231376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Injectable liposomal docosahexaenoic acid alleviates atherosclerosis progression and enhances plaque stability.
    Chong SY; Wang X; van Bloois L; Huang C; Syeda NS; Zhang S; Ting HJ; Nair V; Lin Y; Lou CKL; Benetti AA; Yu X; Lim NJY; Tan MS; Lim HY; Lim SY; Thiam CH; Looi WD; Zharkova O; Chew NWS; Ng CH; Bonney GK; Muthiah M; Chen X; Pastorin G; Richards AM; Angeli V; Storm G; Wang JW
    J Control Release; 2023 Aug; 360():344-364. PubMed ID: 37406819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of Liver X receptors in the heart leads to accumulation of intracellular lipids and attenuation of ischemia-reperfusion injury.
    Lei P; Baysa A; Nebb HI; Valen G; Skomedal T; Osnes JB; Yang Z; Haugen F
    Basic Res Cardiol; 2013 Jan; 108(1):323. PubMed ID: 23266787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats.
    Leik CE; Carson NL; Hennan JK; Basso MD; Liu QY; Crandall DL; Nambi P
    Br J Pharmacol; 2007 Jun; 151(4):450-6. PubMed ID: 17420776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver X receptor agonist GW3965 protects against sepsis by promoting myeloid derived suppressor cells apoptosis in mice.
    Zhang W; Luo M; Zhou Y; Hu J; Li C; Liu K; Liu M; Zhu Y; Chen H; Zhang H
    Life Sci; 2021 Jul; 276():119434. PubMed ID: 33785343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver X receptor agonist GW3965 dose-dependently regulates lps-mediated liver injury and modulates posttranscriptional TNF-alpha production and p38 mitogen-activated protein kinase activation in liver macrophages.
    Wang YY; Dahle MK; Steffensen KR; Reinholt FP; Collins JL; Thiemermann C; Aasen AO; Gustafsson JA; Wang JE
    Shock; 2009 Nov; 32(5):548-53. PubMed ID: 19295476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective Functions of Liver X Receptor α in Established Vulnerable Plaques: Involvement of Regulating Endoplasmic Reticulum-Mediated Macrophage Apoptosis and Efferocytosis.
    Che X; Xiao Q; Song W; Zhang H; Sun B; Geng N; Tao Z; Shao Q; Pu J
    J Am Heart Assoc; 2021 May; 10(10):e018455. PubMed ID: 33969692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of mannose functionalized dendrimeric nanoparticles for targeted delivery to macrophages: use of this platform to modulate atherosclerosis.
    He H; Yuan Q; Bie J; Wallace RL; Yannie PJ; Wang J; Lancina MG; Zolotarskaya OY; Korzun W; Yang H; Ghosh S
    Transl Res; 2018 Mar; 193():13-30. PubMed ID: 29172034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice.
    Hamzah J; Kotamraju VR; Seo JW; Agemy L; Fogal V; Mahakian LM; Peters D; Roth L; Gagnon MK; Ferrara KW; Ruoslahti E
    Proc Natl Acad Sci U S A; 2011 Apr; 108(17):7154-9. PubMed ID: 21482787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plaque-penetrating peptide inhibits development of hypoxic atherosclerotic plaque.
    She ZG; Hamzah J; Kotamraju VR; Pang HB; Jansen S; Ruoslahti E
    J Control Release; 2016 Sep; 238():212-220. PubMed ID: 27423327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the liver X receptor protects against hepatic injury in endotoxemia by suppressing Kupffer cell activation.
    Wang YY; Dahle MK; Agren J; Myhre AE; Reinholt FP; Foster SJ; Collins JL; Thiemermann C; Aasen AO; Wang JE
    Shock; 2006 Feb; 25(2):141-6. PubMed ID: 16525352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LXR activation by GW3965 alters fat tissue distribution and adipose tissue inflammation in ob/ob female mice.
    Archer A; Stolarczyk E; Doria ML; Helguero L; Domingues R; Howard JK; Mode A; Korach-André M; Gustafsson JÅ
    J Lipid Res; 2013 May; 54(5):1300-11. PubMed ID: 23446231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.